Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Patrys Ltd
PABPatrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. The company dvelops Deoxymab 3E10 also called PAT-DX1 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents such as radiation and many chemotherapy drugs. In addition, it develops PAT-DX3, a full-sized antibody that has DNA-targeting properties of PAT-DX1, but different pharmaceutic properties, such as tissue distribution, pharmacokinetic profile, etc. Further, it is involved in DNA targeting, blood-brain barrier, Inhibit NETosis human therapeutic applications. Patrys Limited was incorporated in 2006 and is based in Melbourne, Australia. Address: 96-100 Albert Road, Melbourne, VIC, Australia, 3205
Analytics
WallStreetin tavoitehinta
0.18 AUDP/E-suhde
–Osinkotuotto
–Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut PAB
Osinkoanalytiikka PAB
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
–Osinkohistoria PAB
Osakkeen arvostus PAB
Talousasiat PAB
Tuloksia | 2019 | Dynamiikka |